These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35583259)

  • 1. Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.
    Connolly CM; Frey S; Chiang TP; Teles M; Alejo JL; Albayda J; Shah AA; Werbel WA; Segev DL; Christopher-Stine L; Paik JJ
    Rheumatology (Oxford); 2022 Oct; 61(10):e302-e304. PubMed ID: 35583259
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases.
    Connolly CM; Ruddy JA; Boyarsky BJ; Avery RK; Werbel WA; Segev DL; Garonzik-Wang J; Paik JJ
    Ann Rheum Dis; 2021 Aug; 80(8):1100-1101. PubMed ID: 33741555
    [No Abstract]   [Full Text] [Related]  

  • 3. Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado
    Bourguiba R; Delplanque M; Savey L; Hentgen V; Grateau G; Georgin-Lavialle S;
    Ann Rheum Dis; 2023 Dec; 82(12):e228. PubMed ID: 35817471
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
    Boyarsky BJ; Ruddy JA; Connolly CM; Ou MT; Werbel WA; Garonzik-Wang JM; Segev DL; Paik JJ
    Ann Rheum Dis; 2021 Aug; 80(8):1098-1099. PubMed ID: 33757968
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of inactivated SARS-CoV-2 vaccination in COVID-19-associated pneumonia among patients with rheumatic and musculoskeletal diseases: A real-world retrospective observational study.
    Liu S; Jin Z; Feng X; Da Z; Tang Y; Hu H; Wang D; Sun L
    Int J Rheum Dis; 2024 May; 27(5):e15166. PubMed ID: 38720417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.
    Kroon FPB; Najm A; Alunno A; Schoones JW; Landewé RBM; Machado PM; Navarro-Compán V
    Ann Rheum Dis; 2022 Mar; 81(3):422-432. PubMed ID: 34876462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases.
    Ursini F; Ruscitti P; Raimondo V; De Angelis R; Cacciapaglia F; Pigatto E; Olivo D; Di Cola I; Galluccio F; Francioso F; Foti R; Tavoni A; D'Angelo S; Campochiaro C; Motta F; De Santis M; Bilia S; Bruno C; De Luca G; Visentini M; Ciaffi J; Mancarella L; Brusi V; D'Onghia M; Cuomo G; Fusaro E; Dagna L; Guiducci S; Meliconi R; Iannone F; Iagnocco A; Giacomelli R; Ferri C
    Ann Rheum Dis; 2022 Mar; 81(3):440-441. PubMed ID: 34836886
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
    Fornaro M; Venerito V; Iannone F; Cacciapaglia F
    J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
    [No Abstract]   [Full Text] [Related]  

  • 9. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.
    Landewé RBM; Kroon FPB; Alunno A; Najm A; Bijlsma JW; Burmester GR; Caporali R; Combe B; Conway R; Curtis JR; Elkayam O; Gossec L; Heijstek MW; Haupt L; Iagnocco A; Isaacs JD; Juhász IÁ; Makri S; Mariette X; McInnes IB; Mehta P; Mueller-Ladner U; Schulze-Koops H; Smolen JS; Wiek D; Winthrop KL; Navarro-Compán V; Machado PM
    Ann Rheum Dis; 2022 Dec; 81(12):1628-1639. PubMed ID: 35197264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases.
    Kawazoe M; Nishio J; Hirose W; Furukawa K; Nanki T
    Eur J Intern Med; 2023 Sep; 115():137-139. PubMed ID: 37339924
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines.
    Schulze-Koops H; Specker C; Skapenko A
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33627439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists.
    Priori R; Pellegrino G; Colafrancesco S; Alessandri C; Ceccarelli F; Di Franco M; Riccieri V; Scrivo R; Sili Scavalli A; Spinelli FR; Conti F
    Ann Rheum Dis; 2021 Jul; 80(7):953-954. PubMed ID: 33622689
    [No Abstract]   [Full Text] [Related]  

  • 13. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.
    Connolly CM; Chiang TP; Boyarsky BJ; Ruddy JA; Teles M; Alejo JL; Massie A; Werbel WA; Shah AA; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
    Ann Rheum Dis; 2022 Feb; 81(2):293-295. PubMed ID: 34556484
    [No Abstract]   [Full Text] [Related]  

  • 14. Urticaria 12 Days After COVID-19 mRNA Booster Vaccination.
    Wolfson AR; Freeman EE; Blumenthal KG
    JAMA; 2022 May; 327(17):1702-1703. PubMed ID: 35420647
    [No Abstract]   [Full Text] [Related]  

  • 15. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
    Connolly CM; Boyarsky BJ; Ruddy JA; Werbel WA; Christopher-Stine L; Garonzik-Wang JM; Segev DL; Paik JJ
    Ann Intern Med; 2021 Sep; 174(9):1332-1334. PubMed ID: 34029488
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy.
    Dick A; Rosenbloom JI; Karavani G; Gutman-Ido E; Lessans N; Chill HH
    Am J Obstet Gynecol MFM; 2022 Jul; 4(4):100637. PubMed ID: 35398583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases.
    Lawson-Tovey S; Hyrich KL; Gossec L; Strangfeld A; Carmona L; Raffeiner B; Yardımcı GK; Trefond L; Roux N; Rodrigues A; Papagoras C; Mateus EF; Mariette X; Machado PM
    Ann Rheum Dis; 2022 Jan; 81(1):145-150. PubMed ID: 34489305
    [No Abstract]   [Full Text] [Related]  

  • 18. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
    Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
    Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'.
    Smerilli G; Cipolletta E; Moscioni E; Francioso F; Risa AM; Maccarrone V; Zompa D; Di Matteo A; Di Carlo M; De Angelis R; Salaffi F; Filippucci E; Grassi W
    Ann Rheum Dis; 2021 Oct; 80(10):e168. PubMed ID: 33962960
    [No Abstract]   [Full Text] [Related]  

  • 20. SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.
    Winthrop KL; Whitley RJ; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1249-1251. PubMed ID: 34518198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.